Live Feeds
● LIVE Updated 6h ago Β· 6 sources tracked

Stroke survivors get FDA-approved daily pill shown to cut repeat risk by 26%

The U.S. Food and Drug Administration has approved Sunharbo (asundexian) 50 mg tablets, in combination with antiplatelet therapy, to reduce the risk of stroke in adults following a recent mild-to-moderate noncardioembolic ischemic stroke or high-risk transient ischemic attack. The daily pill represents the first factor XIa inhibitor cleared for this indication. Clinical data showed the treatment cuts repeat stroke risk by 26 percent. Bayer manufactures the drug, which introduces a new class of antithrombotic therapy for secondary stroke prevention.

πŸŽ™οΈ

Listen to Live Briefing

Real-time synthesized voice briefing Β· Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (6)
⚑ Key Developments & Real-Time Context
Text size:
  • βœ“ FDA approved Sunharbo (asundexian) 50 mg tablets for secondary stroke prevention.
  • βœ“ The drug is indicated in combination with antiplatelet therapy for adults after mild-to-moderate noncardioembolic ischemic stroke or high-risk TIA.
  • βœ“ Asundexian is the first factor XIa inhibitor approved for this use.
  • βœ“ Clinical data showed a 26 percent reduction in repeat stroke risk.
πŸ›‘οΈ Source Corroboration: 6 independent reporting domains (90% confidence) ⏱ Read time: ~2 min

What changed

FDA approved Sunharbo (asundexian) as the first factor XIa inhibitor for secondary stroke prevention in adults with recent noncardioembolic ischemic stroke or high-risk TIA.

Live updates

  1. FDA approves first factor XIa inhibitor for secondary stroke prevention

    The U.S. Food and Drug Administration has approved Sunharbo (asundexian) 50 mg tablets, in combination with antiplatelet therapy, to reduce the risk of stroke in adults following a recent mild-to-moderate noncardioembolic ischemic stroke or high-risk transient ischemic attack. The daily pill represents the first factor XIa inhibitor cleared for this indication. Clinical data showed the treatment cuts repeat stroke risk by 26 percent. Bayer manufactures the drug, which introduces a new class of antithrombotic therapy for secondary stroke prevention.

    Why it matters

    Factor XIa inhibitors target a different part of the coagulation cascade than older anticoagulants, aiming to prevent clots while preserving hemostasis and lowering bleeding risk. Until now, secondary prevention relied mainly on antiplatelet agents and direct oral anticoagulants for cardioembolic sources. A new mechanism expands options for patients with noncardioembolic strokes who remain at elevated recurrence risk.

    What is confirmed

    • FDA approved Sunharbo (asundexian) 50 mg tablets for secondary stroke prevention.
    • The drug is indicated in combination with antiplatelet therapy for adults after mild-to-moderate noncardioembolic ischemic stroke or high-risk TIA.
    • Asundexian is the first factor XIa inhibitor approved for this use.
    • Clinical data showed a 26 percent reduction in repeat stroke risk.
    • Bayer manufactures the drug.

    What to watch next

    • Post-marketing safety data on bleeding rates in real-world use
    • Guideline updates from AHA/ASA incorporating factor XIa inhibitors
    • Insurance coverage and formulary placement decisions
    Sources used for this update (6)
    1. WSJ β€” New Type of Blood Thinner Approved to Prevent Repeat Strokes
    2. STAT β€” FDA approves novel Bayer drug to reduce recurrence of stroke
    3. Fox News β€” Stroke survivors get FDA-approved daily pill shown to cut repeat risk by 26%
    4. Time Magazine β€” A New Pill Could Reduce the Risk of Having a Second Stroke
    5. Pharmacy Times β€” Formulary Fit: Preparing Pathways and Protocols for a New Class of Antithrombotic Therapy
    6. medicalxpress.com β€” FDA approves first factor XIa inhibitor for secondary stroke prevention
    confidence 90%
πŸ“Š

Community Sentiment: How do you assess this situation?

Voice your perspective Β· Real-time aggregated sentiment from the Live Feeds community